Giovanni Vitulli

Giovanni Vitulli

Auto-generated profile, based on publicly available information

Giovanni Vitulli

Fibrosis DPU, Respiratory TAU, GlaxoSmithKline, Stevenage, Hertfordshire, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AJAlison E. John
Alison E. John
RGRebecca H. Graves
Rebecca H. Graves
KPK. Tao Pun
K. Tao Pun
GVGiovanni Vitulli
Giovanni Vitulli
EFEllen J. Forty
Ellen J. Forty
RSRobert John Slack
Robert John Slack
The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF). We identified a selective small molecule αvβ6 RGD-mimetic, GSK3008348, and profiled it in a range of disease relevant pre-clinical systems. To understand the relationship between target engagement and inhibition of fibrosis, we measured pharmacodynamic and disease-related end points. Here, we report, GSK3008348 binds to αvβ6 with high affinity in human IPF lung and reduces downstream pro-fibrotic TGFβ signaling to normal levels. In human lung epithelial cells, GSK3008348 induces rapid internalization and lysosomal degradation of the αvβ6 integrin. In the murine bleomycin-induced lung fibrosis model, GSK3008348 engages αvβ6, induces prolonged inhibition of TGFβ signaling and reduces lung collagen deposition and serum C3M, a marker of IPF disease progression. These studies highlight the potential of inhaled GSK3008348 as an anti-fibrotic therapy.

1 January 1998 in Journal of Organometallic Chemistry
Verified
Journal Article
Closed access
PPPaolo Pertici
Paolo Pertici
AVAlessandra Verrazzani
Alessandra Verrazzani
GVGiovanni Vitulli
Giovanni Vitulli
RBRichard Baldwin
Richard Baldwin
MBMartin A. Bennett
Martin A. Bennett